Eton Pharmaceuticals (ETON)
(Delayed Data from NSDQ)
$5.94 USD
+0.03 (0.51%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $5.93 -0.01 (-0.17%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Income Statements
Fiscal Year end for Eton Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 32 | 21 | 22 | 0 | 1 |
Cost Of Goods | 11 | 7 | 3 | 0 | 0 |
Gross Profit | 21 | 14 | 19 | 0 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 22 | 23 | 21 | 27 | 19 |
Income After Depreciation & Amortization | -1 | -8 | -2 | -27 | -19 |
Non-Operating Income | 1 | -1 | 0 | -1 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -1 | -9 | -2 | -28 | -18 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -1 | -9 | -2 | -28 | -18 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -1 | -9 | -2 | -28 | -18 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -6 | -1 | -26 | -18 |
Depreciation & Amortization (Cash Flow) | 1 | 2 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -1 | -8 | -2 | -27 | -19 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 25.65 | 25.15 | 25.21 | 21.01 | 17.76 |
Diluted EPS Before Non-Recurring Items | -0.04 | -0.36 | -0.08 | -1.33 | -1.03 |
Diluted Net EPS (GAAP) | -0.04 | -0.36 | -0.08 | -1.33 | -1.03 |
Fiscal Year end for Eton Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 9.07 | 7.97 | 7.31 | 7.03 | 12.00 |
Cost Of Goods | 3.45 | 2.96 | 3.68 | 2.63 | 2.32 |
Gross Profit | 5.63 | 5.01 | 3.63 | 4.40 | 9.68 |
SG&A, R&D, and Dept/Amort Expenses | 8.56 | 5.81 | 5.63 | 4.96 | 5.80 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.93 | -0.80 | -2.00 | -0.56 | 3.88 |
Non-Operating Income | 0.00 | 0.00 | -0.30 | 0.00 | 0.80 |
Interest Expense | 0.05 | 0.01 | -0.28 | 0.03 | 0.12 |
Pretax Income | -2.99 | -0.81 | -2.01 | -0.58 | 4.56 |
Income Taxes | 0.05 | 0.00 | 0.25 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -3.04 | -0.81 | -2.26 | -0.58 | 4.56 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -3.04 | -0.81 | -2.26 | -0.58 | 4.56 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 25.78 | 25.76 | 25.74 | 25.72 | 25.98 |
Diluted EPS Before Non-Recurring Items | -0.12 | -0.03 | -0.09 | -0.02 | 0.18 |
Diluted Net EPS (GAAP) | -0.12 | -0.03 | -0.10 | -0.02 | 0.18 |